GlassScriptPhysician profile
Kathleen Powers
NPI 1689386112
$1,275.44
in general payments reported to CMS, 2019-2025
19 companies · $717 in 2025
The $717 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $115 · 2024: $443 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $361.03 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $200.37 | 2023-2025 | |
| Glaxosmithkline, LLC. | $153.58 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $84.86 | 2024-2025 | |
| Daiichi Sankyo INC. | $78.18 | 2024-2025 | Injectafer |
| Exact Sciences Corporation | $59.70 | 2023-2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $47.23 | 2023-2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $39.87 | 2025 | Rexulti |
| Lilly USA, LLC | $39.67 | 2025 | Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.83 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $25.67 | 2025 | Fanapt, Hetlioz |
| Inogen, INC. | $23.11 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.81 | 2025 | Xifaxan |
| Axsome Therapeutics, INC. | $21.65 | 2025 | Auvelity |
| Ardelyx, INC. | $21.50 | 2025 | Ibsrela |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21.29 | 2025 | General - Female Sui |
| Merck Sharp & Dohme LLC | $17.17 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Medtronic, INC. | $16.18 | 2024 | Intellis Adaptivestim |
| Mylan Specialty L.P. | $13.74 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.